Your AI-Trained Oncology Knowledge Connection!
February 16, 2021 - Itolizumab, a humanized IgG1 monoclonal antibody that modulates the activated leukocyte cell adhesion molecule pathway, represents a promising approach for the treatment of patients with newly diagnosed acute graft-versus-host disease.
During a recent OncLive Peer Exchange®, a panel of experts in kidney cancer from the United States and France convened to discuss several important immunotherapy studies presented during the ESMO Virtual Congress 2020, as well as several others that are under way and expected to report out over the next few years.
Binod Dhakal, MD, discusses responses achieved with orvacabtagene autoleucel in patients with multiple myeloma.
Jing-Yi Chern, MD, ScM, discusses efforts being made to combine PARP inhibitors with chemotherapy and immunotherapy in patients with recurrent ovarian cancer.
Christopher R. D’Angelo, MD, discusses advances made with CAR T-cell therapy in lymphoma.
Finding a reliable biomarker for minimal residual disease assessment is needed and circulating tumor DNA has shown incredible promise in colon cancer.
February 15, 2021 - Betibeglogene autotemcel, a one-time gene therapy, enabled durable transfusion independence in most patients with transfusion-dependent β-thalassemia who were treated across 4 clinical studies.
Narendranath Epperla, MD, MS, expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline.
February 15, 2021 - Zanidatamab demonstrated promising antitumor activity with favorable tolerability in patients with HER2-expressing gastroesophageal adenocarcinoma that has progressed following previous therapies, including HER2-targeted agents.
February 15, 2021 - The combination of lurbinectedin and irinotecan following relapse on frontline treatment was found to induce promising antitumor activity in patients with small cell lung cancer.
NBTXR3, a novel radioenhancer, is showing intriguing response rates in adult patient with soft tissue sarcoma, paving a path for the innovative therapy not just in sarcomas, but other tumor types, as well.
Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.
Robert L. Coleman, MD, discusses key data for these therapies and touched on emerging developments concerning new therapies in ovarian and endometrial cancers.
Randy Stevens, MD, discusses the growing role for radiation in lung cancer, delivery techniques, and adverse effect management strategies.
February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.
February 13, 2021 - Lenvatinib in combination with pembrolizumab resulted in improved overall survival, progression-free survival, and objective response rate over sunitinib in the frontline treatment of patients with advanced renal cell carcinoma.
February 13, 2021 - Belzutifan used in combination with cabozantinib shrank tumors for 88% of patients and the disease control rate was 90% for patients with previously treated advanced clear cell renal cell carcinoma.
February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ
February 13, 2021 - Reductions in prostate-specific antigen screening are likely responsible for the recent increase in metastatic prostate cancer cases in the United States.
February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.
Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.
Tanya Dorff, MD, discusses the effects of bright white light therapy on obese frailty in older men with prostate cancer.
February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.
February 13, 2021 - Treatment with apalutamide plus androgen-deprivation therapy reduced the risk of death by 35% versus ADT alone in patients with metastatic castration-sensitive prostate cancer.
February 13, 2021 - Nivolumab following surgery extended disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma.
February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
February 12, 2021 - Cabozantinib demonstrated significant intracranial and extracranial responses in patients with metastatic renal cell carcinoma who have brain metastases.
